Phase 2 Intermediate Risk Clinical Trials
5 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–5 of 5 trials
Recruiting
Phase 2
VA Consolidation in Intermediate-Risk AML
Acute Myeloid LeukemiaConsolidation TherapyIntermediate Risk Acute Myeloid Leukemia
The First Affiliated Hospital of Soochow University226 enrolled1 locationNCT07672262
Recruiting
Phase 2
Androgen-responsive POSLUMA-guided Intra-prostatic Boost
Prostate CancerHigh-risk Prostate CancerIntermediate Risk Prostate Cancer
Martin T. King, MD, PhD23 enrolled4 locationsNCT07393867
Recruiting
Phase 2
Gilteritinib Plus VA Followed By Consolidation Chemotherapy in Newly Diagnosed FLT3-ITD+ AML
Acute Myeloid LeukemiaIntermediate Risk Acute Myeloid LeukemiaFLT3 Internal Tandem Duplication Positive+1 more
First Affiliated Hospital of Zhejiang University25 enrolled1 locationNCT07259707
Recruiting
Phase 2
Efbemalenograstim Alfa for Primary/Secondary Prevention in Patients With Solid Tumors at High Risk for Febrile Neutropenia (FN) or Intermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in FN
Primary/Secondary PreventionHigh Risk for Febrile Neutropenia of Chemotherapy RegimensIntermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in Febrile Neutropenia
Henan Cancer Hospital1,076 enrolled1 locationNCT07187908
Recruiting
Phase 2
Study of VA Combined With HAAG Regimen in Newly Diagnosed Intermediate and High-risk AML Patients
High-Risk Acute Myeloid LeukemiaIntermediate Risk Acute Myeloid Leukemia
The First Affiliated Hospital of Soochow University60 enrolled1 locationNCT06394011